Total Returns (Price + Dividend) 
Goldline Pharmac for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Declaration Of Un-Audited Standalone Financial Results Of The Company For The Half Year Ended September 30 2026
14-Nov-2026 | Source : BSEDeclaration of Un-audited Standalone Financial Results of the company for the half year ended September 30 2026
Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th November 2026 Pursuant To Reg 30 And Other Applicable Provisions Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
14-Nov-2026 | Source : BSEOutcome of Board Meeting dated 14th November 2026 pursuant to Reg 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 & Submission of Un-audited Standalone Financial Results of the Company for the half year ended September 30 2026.
Submission Of Statement Of Deviation(S) Or Variation(S) Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) For The Half Year Ended 30Th September 2026.
14-Nov-2026 | Source : BSESubmission of statement of deviation and variation of the half year ended 30th september 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.31%)
Swapan Kumar Khandelwal (30.08%)
Sumit Bilgaiyan (7.06%)
34.32%